A novel anti-inflammatory treatment for bradykinin-induced sore throat or pharyngitis
Victor Leyva-Grado, Pavel Pugach, Nazlie Sadeghi-Latefi, Victor Leyva-Grado, Pavel Pugach, Nazlie Sadeghi-Latefi
Abstract
Background: Often thought of as a minor health concern, sore throat or pharyngitis is an important public health issue. It is one of the most common symptoms of upper respiratory diseases including COVID-19 and is a leading cause of physician visits and antibiotic prescriptions. However, few over-the-counter medications are proven to heal sore throat inflammation.
Methods: Adenocarcinomic human alveolar basal epithelial cells (A549 cells) and three dimensional organotypic human respiratory tissues were used to study inflammation and various treatment effects on respiratory epithelia. The cells and tissues were studied both in the presence and absence of bradykinin, one of the first inflammatory mediators of pharyngitis. Inflammation was measured by analyzing the levels of prostaglandin E2 (PGE2), interleukin 8 (IL-8), and leukotriene B4 (LTB4), transepithelial electrical resistance (TEER), and lactate dehydrogenase (LDH) release. Tissue morphology was analyzed by immunohistochemistry.
Results: In studying pharyngitis using organotypic human respiratory tissue stimulated with bradykinin, we saw an increase in PGE2 and interleukin-8 (IL-8) in response to bradykinin. Acetyl salicylic acid (ASA), a nonspecific COX inhibitor, was able to mitigate a bradykinin-induced increase in PGE2 in our studies. However, ASA was inflammatory above its therapeutic window, increasing the levels of PGE2 and IL-8 above those seen with bradykinin stimulation alone. We describe a novel, scientifically validated treatment for sore throat, that contains a low dose of ASA and other anti-inflammatory ingredients.
Conclusion: This study elucidates the complex mechanisms involved in healing pharyngitis, an inflammatory condition of the upper respiratory epithelia. An ASA-based formula (Biovanta) mitigated bradykinin-induced inflammation more strongly than ASA alone in organotypic human respiratory tissues. Surprisingly, we found that many of the most common over the counter sore throat therapies exacerbate inflammation and IL-8 in organotypic human respiratory tissues, suggesting these common treatments may increase the likelihood of further respiratory complications.
Keywords: Bradykinin; Epiairway; MucilAir; acetyl salicylic acid; pharyngitis; prostaglandin.
© 2021 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
Figures
References
- Aspley S, Shephard A, Schachtel E, Sanner K, Savino L, Schachtel B. Efficacy of flurbiprofen 8.75 mg lozenge in patients with a swollen and inflamed sore throat. Curr Med Res Opin. 2016;32(9):1529‐1538.
- Sykes EA, Wu V, Beyea MM, Simpson MTW, Beyea JA. Pharyngitis: approach to diagnosis and treatment. Can Fam Physician. 2020;66(4):251‐257.
- Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis. 2012;55(10):1279‐1282.
- Yoon YK, Park CS, Kim JW, et al. Guidelines for the antibiotic use in adults with acute upper respiratory tract infections. Infect Chemother. 2017;49(4):326‐352.
- Farrer F. Sprays and lozenges for sore throats. S Afr Pharm J. 2011;78(4):26‐31.
- Group ESTG, Pelucchi C, Grigoryan L, et al. Guideline for the management of acute sore throat. Clin Microbiol Infect. 2012;18(Suppl 1):1‐28.
- Schachtel B, Aspley S, Shephard A, Shea T, Smith G, Schachtel E. Utility of the sore throat pain model in a multiple‐dose assessment of the acute analgesic flurbiprofen: a randomized controlled study. Trials. 2014;15:263.
- Williams K, Roman J. Studying human respiratory disease in animals‐‐role of induced and naturally occurring models. J Pathol. 2016;238(2):220‐232.
- Pampaloni F, Reynaud EG, Stelzer EH. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol. 2007;8(10):839‐845.
- Sheasgreen J, Klausner M, Kandarova H, Ingalls D. The MatTek story—how the three Rs principles led to 3‐D tissue success! Altern Lab Anim. 2009;37(6):611‐622.
- Al‐Sayed AA, Agu RU, Massoud E. Models for the study of nasal and sinus physiology in health and disease: a review of the literature. Laryngoscope Investig Otolaryngol. 2017;2(6):398‐409.
- Edouard S, Million M, Bachar D, et al. The nasopharyngeal microbiota in patients with viral respiratory tract infections is enriched in bacterial pathogens. Eur J Clin Microbiol Infect Dis. 2018;37(9):1725‐1733.
- Doyle WJ, Boehm S, Skoner DP. Physiologic responses to intranasal dose‐response challenges with histamine, methacholine, bradykinin, and prostaglandin in adult volunteers with and without nasal allergy. J Allergy Clin Immunol. 1990;86(6 Pt 1):924‐935.
- Proud D, Reynolds CJ, Lacapra S, Kagey‐Sobotka A, Lichtenstein LM, Naclerio RM. Nasal provocation with bradykinin induces symptoms of rhinitis and a sore throat. Am Rev Respir Dis. 1988;137(3):613‐616.
- Pang L, Knox AJ. Bradykinin stimulates IL‐8 production in cultured human airway smooth muscle cells: role of cyclooxygenase products. J Immunol. 1998;161(5):2509‐2515.
- Rodgers HC, Pang L, Holland E, Corbett L, Range S, Knox AJ. Bradykinin increases IL‐8 generation in airway epithelial cells via COX‐2‐derived prostanoids. Am J Physiol Lung Cell Mol Physiol. 2002;283(3):L612‐L618.
- Rees GL, Eccles R. Sore throat following nasal and oropharyngeal bradykinin challenge. Acta Otolaryngol. 1994;114(3):311‐314.
- Jug M, Hafner A, Lovrić J, et al. An overview of in vitro dissolution/release methods for novel mucosal drug delivery systems. J Pharm Biomed Anal. 2018;147:350‐366.
- Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S. NS‐398, a new anti‐inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX‐2) activity in vitro. Prostaglandins. 1994;47(1):55‐59.
- Huang S, Wiszniewski L, Constant S. The use of in vitro 3D cell models in drug development for respiratory diseases. Drug discovery and development ‐ present and future; 2011:169–190. 10.5772/28132
- Iverson E, Kaler L, Agostino EL, Song D, Duncan GA, Scull MA. Leveraging 3D model systems to understand viral interactions with the respiratory mucosa. Viruses. 2020;12(12):1425.
- Kia'i N, Bajaj T. Histology, respiratory epithelium. Treasure Island, FL: StatPearls Publishing; 2020.
- Sayed N, Liu C, Wu JC. Translation of human‐induced pluripotent stem cells: from clinical trial in a dish to precision medicine. J Am Coll Cardiol. 2016;67(18):2161‐2176.
- Balogh Sivars K, Sivars U, Hornberg E, et al. A 3D Human airway model enables prediction of respiratory toxicity of inhaled drugs in vitro. Toxicol Sci. 2018;162(1):301‐308.
- Edwards WP. Royal Society of Chemistry (Great Britain). The science of sugar confectionery. 166. Cambridge: Royal Society of Chemistry; 2000:px.
- Kim SY, Chang YJ, Cho HM, Hwang YW, Moon YS. Non‐steroidal anti‐inflammatory drugs for the common cold. Cochrane Database Syst Rev. 2015;9:CD006362
- Fisman EZ, Grossman E, Motro M, Tenenbaum A. Clinical evidence of dose‐dependent interaction between aspirin and angiotensin‐converting enzyme inhibitors. J Hum Hypertens. 2002;16(6):379‐383.
- Tenenbaum A, Grossman E, Shemesh J, Fisman EZ, Nosrati I, Motro M. Intermediate but not low doses of aspirin can suppress angiotensin‐converting enzyme inhibitor‐induced cough. Am J Hypertens. 2000;13(7):776‐782.
- Brash AR. Arachidonic acid as a bioactive molecule. J Clin Invest. 2001;107(11):1339‐1345.
- Bisgaard H. Role of leukotrienes in asthma pathophysiology. Pediatr Pulmonol. 2000;30(2):166‐176.
- Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal antiinflammatory drug‐mediated apoptosis. Proc Natl Acad Sci USA. 1998;95(2):681‐686.
- Störmann P, Auner B, Schimunek L, et al. Leukotriene B4 indicates lung injury and on‐going inflammatory changes after severe trauma in a porcine long‐term model. Prostaglandins Leukot Essent Fatty Acids. 2017;127:25‐31.
- McCain RW, Holden EP, Blackwell TR, Christman JW. Leukotriene B4 stimulates human polymorphonuclear leukocytes to synthesize and release interleukin‐8 in vitro. Am J Respir Cell Mol Biol. 1994;10(6):651‐657.
- Le Bel M, Brunet A, Gosselin J. Leukotriene B4, an endogenous stimulator of the innate immune response against pathogens. J Innate Immun. 2014;6(2):159‐168.
- Thoren S, Jakobsson PJ. Coordinate up‐ and down‐regulation of glutathione‐dependent prostaglandin E synthase and cyclooxygenase‐2 in A549 cells. Inhibition by NS‐398 and leukotriene C4. Eur J Biochem. 2000;267(21):6428‐6434.
- Huang M, Stolina M, Sharma S, et al. Non‐small cell lung cancer cyclooxygenase‐2‐dependent regulation of cytokine balance in lymphocytes and macrophages: up‐regulation of interleukin 10 and down‐regulation of interleukin 12 production. Cancer Res. 1998;58(6):1208‐1216.
- Takai E, Tsukimoto M, Kojima S. TGF‐beta1 downregulates COX‐2 expression leading to decrease of PGE2 production in human lung cancer A549 cells, which is involved in fibrotic response to TGF‐beta1. PLOS One. 2013;8(10):e76346.
- Van de Veerdonk FL, Netea MG, Van Deuren M, et al. Kallikrein‐kinin blockade in patients with COVID‐19 to prevent acute respiratory distress syndrome. eLife. 2020;9:9.
- Garvin MR, Alvarez C, Miller JI, et al. A mechanistic model and therapeutic interventions for COVID‐19 involving a RAS‐mediated bradykinin storm. eLife. 2020;9:9.
- Chow JH, Khanna AK, Kethireddy S, et al. Aspirin use is associated with decreased mechanical ventilation, ICU admission, and in‐hospital mortality in hospitalized patients with COVID‐19. Anesth Analg. 2020;132:930‐941.
- Hogman M, Mork AC, Roomans GM. Hypertonic saline increases tight junction permeability in airway epithelium. Eur Respir J. 2002;20(6):1444‐1448.
- Schwartz L, Guais A, Pooya M, Abolhassani M. Is inflammation a consequence of extracellular hyperosmolarity? J Inflamm. 2009;6:21.
Source: PubMed